Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory
Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes, by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin therapy is obligatory, resveratrol treatment has never been investigated. The prese...
Gespeichert in:
| Veröffentlicht in: | Nutrition & metabolism 2016-06, Vol.13 (1), p.44-44, Article 44 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 44 |
|---|---|
| container_issue | 1 |
| container_start_page | 44 |
| container_title | Nutrition & metabolism |
| container_volume | 13 |
| creator | Yonamine, Caio Yogi Pinheiro-Machado, Erika Michalani, Maria Luiza Freitas, Helayne Soares Okamoto, Maristela Mitiko Corrêa-Giannella, Maria Lucia Machado, Ubiratan Fabres |
| description | Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes, by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin therapy is obligatory, resveratrol treatment has never been investigated. The present study aimed to evaluate resveratrol as an adjunctive agent to insulin therapy in a T1D-like experimental model.
Rats were rendered diabetic by streptozotocin (STZ) treatment. Twenty days later, four groups of animals were studied: non-diabetic (ND); diabetic treated with placebo (DP); diabetic treated with insulin (DI) and diabetic treated with insulin plus resveratrol (DIR). After 30 days of treatment, 24-hour urine was collected; then, blood, soleus muscle, proximal small intestine, renal cortex and liver were sampled. Specific glucose transporter proteins were analyzed (Western blotting) in each territory of interest. Solute carrier family 2 member 2 (Slc2a2), phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase catalytic subunit (G6pc) mRNAs (qPCR), glycogen storage and sirtuin 1 (SIRT1) activity were analyzed in liver.
Diabetes induction increased blood glucose, plasma fructosamine concentrations, and glycosuria. Insulin therapy partially recovered the glycemic control; however, resveratrol as adjunctive therapy additionally improved glycemic control and restored plasma fructosamine concentration to values of non-diabetic rats. Resveratrol did not alter the expression of the glucose transporters GLUT2 and SGLT1 in the intestine, GLUT2 and SGLT2 in kidney and GLUT4 in soleus, suggesting that fluxes of glucose in these territories were unaltered. Differently, in liver, resveratrol promoted a reduction in Slc2a2, Pck1, and G6pc mRNAs, as well as in GLUT2 protein (P |
| doi_str_mv | 10.1186/s12986-016-0103-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4928352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468882702</galeid><sourcerecordid>A468882702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-84547dacafdd825c6f29c8ed6a0e2b1e6337c699d352e2dc3f89f0de941382713</originalsourceid><addsrcrecordid>eNptUstu1DAUtRCIloEPYIMssYFFih-J47CoVFU8KlVCKrC2PPbNjKvEDrYzYv4ehymlg5Cf1z7nXD8OQi8pOaNUineJsk6KitClEV6RR-iUtjWvWtI2jx_MT9CzlG4J4bzuyFN0wlouBCPkFPkbSDuIOscwYDdOMewg4c2wNzA6g03whx1fapoH56scQWew2Dq9hlwwhZze40nHErhJZxc8Dj3OW8BbWGKDM8Tocoj75-hJr4cEL-7GFfr-8cO3y8_V9ZdPV5cX15VpmMyVrJu6tdro3lrJGiN61hkJVmgCbE1BcN4a0XWWNwyYNbyXXU8sdDXlkrWUr9D5QXea1yNYA-UaelBTdKOOexW0U8c73m3VJuxU3TFZRIvAmzuBGH7MkLIaXTIwDNpDmJOiktCaE1q6FXr9D_Q2zNGX6_1GsaahUv5FbfQAyvk-lLxmEVUXtZCyHJssac_-gyrFLt8RPPSurB8R3h4Rlg-Dn3mj55TU1debYyw9YE0MKUXo79-DErUYSh0MpYqh1GIoRQrn1cOHvGf8cRD_BcIrxtw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1801255188</pqid></control><display><type>article</type><title>Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Yonamine, Caio Yogi ; Pinheiro-Machado, Erika ; Michalani, Maria Luiza ; Freitas, Helayne Soares ; Okamoto, Maristela Mitiko ; Corrêa-Giannella, Maria Lucia ; Machado, Ubiratan Fabres</creator><creatorcontrib>Yonamine, Caio Yogi ; Pinheiro-Machado, Erika ; Michalani, Maria Luiza ; Freitas, Helayne Soares ; Okamoto, Maristela Mitiko ; Corrêa-Giannella, Maria Lucia ; Machado, Ubiratan Fabres</creatorcontrib><description>Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes, by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin therapy is obligatory, resveratrol treatment has never been investigated. The present study aimed to evaluate resveratrol as an adjunctive agent to insulin therapy in a T1D-like experimental model.
Rats were rendered diabetic by streptozotocin (STZ) treatment. Twenty days later, four groups of animals were studied: non-diabetic (ND); diabetic treated with placebo (DP); diabetic treated with insulin (DI) and diabetic treated with insulin plus resveratrol (DIR). After 30 days of treatment, 24-hour urine was collected; then, blood, soleus muscle, proximal small intestine, renal cortex and liver were sampled. Specific glucose transporter proteins were analyzed (Western blotting) in each territory of interest. Solute carrier family 2 member 2 (Slc2a2), phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase catalytic subunit (G6pc) mRNAs (qPCR), glycogen storage and sirtuin 1 (SIRT1) activity were analyzed in liver.
Diabetes induction increased blood glucose, plasma fructosamine concentrations, and glycosuria. Insulin therapy partially recovered the glycemic control; however, resveratrol as adjunctive therapy additionally improved glycemic control and restored plasma fructosamine concentration to values of non-diabetic rats. Resveratrol did not alter the expression of the glucose transporters GLUT2 and SGLT1 in the intestine, GLUT2 and SGLT2 in kidney and GLUT4 in soleus, suggesting that fluxes of glucose in these territories were unaltered. Differently, in liver, resveratrol promoted a reduction in Slc2a2, Pck1, and G6pc mRNAs, as well as in GLUT2 protein (P < 0.05, DIR vs. DI); besides, it increased (P < 0.01, DIR vs. DI) the hepatic glycogen content, and SIRT1 protein.
Resveratrol is able to improve glycemic control in insulin-treated T1D-like rats. This effect seems not to involve changes in glucose fluxes in the small intestine, renal proximal tubule, and soleus skeletal muscle; but to be related to several changes in the liver, where downregulation of Slc2a2/GLUT2, Pck1, and G6pc expression was observed, favoring reduction of glucose production and efflux. Besides, resveratrol increased SIRT1 nuclear protein content in liver, which may be related to the observed gene expression regulations.</description><identifier>ISSN: 1743-7075</identifier><identifier>EISSN: 1743-7075</identifier><identifier>DOI: 10.1186/s12986-016-0103-0</identifier><identifier>PMID: 27366200</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Diet therapy ; Genetic aspects ; Metabolism ; Nutrition ; Physiological aspects ; Resveratrol ; Type 1 diabetes</subject><ispartof>Nutrition & metabolism, 2016-06, Vol.13 (1), p.44-44, Article 44</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-84547dacafdd825c6f29c8ed6a0e2b1e6337c699d352e2dc3f89f0de941382713</citedby><cites>FETCH-LOGICAL-c528t-84547dacafdd825c6f29c8ed6a0e2b1e6337c699d352e2dc3f89f0de941382713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928352/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928352/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27366200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yonamine, Caio Yogi</creatorcontrib><creatorcontrib>Pinheiro-Machado, Erika</creatorcontrib><creatorcontrib>Michalani, Maria Luiza</creatorcontrib><creatorcontrib>Freitas, Helayne Soares</creatorcontrib><creatorcontrib>Okamoto, Maristela Mitiko</creatorcontrib><creatorcontrib>Corrêa-Giannella, Maria Lucia</creatorcontrib><creatorcontrib>Machado, Ubiratan Fabres</creatorcontrib><title>Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory</title><title>Nutrition & metabolism</title><addtitle>Nutr Metab (Lond)</addtitle><description>Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes, by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin therapy is obligatory, resveratrol treatment has never been investigated. The present study aimed to evaluate resveratrol as an adjunctive agent to insulin therapy in a T1D-like experimental model.
Rats were rendered diabetic by streptozotocin (STZ) treatment. Twenty days later, four groups of animals were studied: non-diabetic (ND); diabetic treated with placebo (DP); diabetic treated with insulin (DI) and diabetic treated with insulin plus resveratrol (DIR). After 30 days of treatment, 24-hour urine was collected; then, blood, soleus muscle, proximal small intestine, renal cortex and liver were sampled. Specific glucose transporter proteins were analyzed (Western blotting) in each territory of interest. Solute carrier family 2 member 2 (Slc2a2), phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase catalytic subunit (G6pc) mRNAs (qPCR), glycogen storage and sirtuin 1 (SIRT1) activity were analyzed in liver.
Diabetes induction increased blood glucose, plasma fructosamine concentrations, and glycosuria. Insulin therapy partially recovered the glycemic control; however, resveratrol as adjunctive therapy additionally improved glycemic control and restored plasma fructosamine concentration to values of non-diabetic rats. Resveratrol did not alter the expression of the glucose transporters GLUT2 and SGLT1 in the intestine, GLUT2 and SGLT2 in kidney and GLUT4 in soleus, suggesting that fluxes of glucose in these territories were unaltered. Differently, in liver, resveratrol promoted a reduction in Slc2a2, Pck1, and G6pc mRNAs, as well as in GLUT2 protein (P < 0.05, DIR vs. DI); besides, it increased (P < 0.01, DIR vs. DI) the hepatic glycogen content, and SIRT1 protein.
Resveratrol is able to improve glycemic control in insulin-treated T1D-like rats. This effect seems not to involve changes in glucose fluxes in the small intestine, renal proximal tubule, and soleus skeletal muscle; but to be related to several changes in the liver, where downregulation of Slc2a2/GLUT2, Pck1, and G6pc expression was observed, favoring reduction of glucose production and efflux. Besides, resveratrol increased SIRT1 nuclear protein content in liver, which may be related to the observed gene expression regulations.</description><subject>Diet therapy</subject><subject>Genetic aspects</subject><subject>Metabolism</subject><subject>Nutrition</subject><subject>Physiological aspects</subject><subject>Resveratrol</subject><subject>Type 1 diabetes</subject><issn>1743-7075</issn><issn>1743-7075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUstu1DAUtRCIloEPYIMssYFFih-J47CoVFU8KlVCKrC2PPbNjKvEDrYzYv4ehymlg5Cf1z7nXD8OQi8pOaNUineJsk6KitClEV6RR-iUtjWvWtI2jx_MT9CzlG4J4bzuyFN0wlouBCPkFPkbSDuIOscwYDdOMewg4c2wNzA6g03whx1fapoH56scQWew2Dq9hlwwhZze40nHErhJZxc8Dj3OW8BbWGKDM8Tocoj75-hJr4cEL-7GFfr-8cO3y8_V9ZdPV5cX15VpmMyVrJu6tdro3lrJGiN61hkJVmgCbE1BcN4a0XWWNwyYNbyXXU8sdDXlkrWUr9D5QXea1yNYA-UaelBTdKOOexW0U8c73m3VJuxU3TFZRIvAmzuBGH7MkLIaXTIwDNpDmJOiktCaE1q6FXr9D_Q2zNGX6_1GsaahUv5FbfQAyvk-lLxmEVUXtZCyHJssac_-gyrFLt8RPPSurB8R3h4Rlg-Dn3mj55TU1debYyw9YE0MKUXo79-DErUYSh0MpYqh1GIoRQrn1cOHvGf8cRD_BcIrxtw</recordid><startdate>20160629</startdate><enddate>20160629</enddate><creator>Yonamine, Caio Yogi</creator><creator>Pinheiro-Machado, Erika</creator><creator>Michalani, Maria Luiza</creator><creator>Freitas, Helayne Soares</creator><creator>Okamoto, Maristela Mitiko</creator><creator>Corrêa-Giannella, Maria Lucia</creator><creator>Machado, Ubiratan Fabres</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160629</creationdate><title>Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory</title><author>Yonamine, Caio Yogi ; Pinheiro-Machado, Erika ; Michalani, Maria Luiza ; Freitas, Helayne Soares ; Okamoto, Maristela Mitiko ; Corrêa-Giannella, Maria Lucia ; Machado, Ubiratan Fabres</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-84547dacafdd825c6f29c8ed6a0e2b1e6337c699d352e2dc3f89f0de941382713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Diet therapy</topic><topic>Genetic aspects</topic><topic>Metabolism</topic><topic>Nutrition</topic><topic>Physiological aspects</topic><topic>Resveratrol</topic><topic>Type 1 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yonamine, Caio Yogi</creatorcontrib><creatorcontrib>Pinheiro-Machado, Erika</creatorcontrib><creatorcontrib>Michalani, Maria Luiza</creatorcontrib><creatorcontrib>Freitas, Helayne Soares</creatorcontrib><creatorcontrib>Okamoto, Maristela Mitiko</creatorcontrib><creatorcontrib>Corrêa-Giannella, Maria Lucia</creatorcontrib><creatorcontrib>Machado, Ubiratan Fabres</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrition & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yonamine, Caio Yogi</au><au>Pinheiro-Machado, Erika</au><au>Michalani, Maria Luiza</au><au>Freitas, Helayne Soares</au><au>Okamoto, Maristela Mitiko</au><au>Corrêa-Giannella, Maria Lucia</au><au>Machado, Ubiratan Fabres</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory</atitle><jtitle>Nutrition & metabolism</jtitle><addtitle>Nutr Metab (Lond)</addtitle><date>2016-06-29</date><risdate>2016</risdate><volume>13</volume><issue>1</issue><spage>44</spage><epage>44</epage><pages>44-44</pages><artnum>44</artnum><issn>1743-7075</issn><eissn>1743-7075</eissn><abstract>Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes, by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin therapy is obligatory, resveratrol treatment has never been investigated. The present study aimed to evaluate resveratrol as an adjunctive agent to insulin therapy in a T1D-like experimental model.
Rats were rendered diabetic by streptozotocin (STZ) treatment. Twenty days later, four groups of animals were studied: non-diabetic (ND); diabetic treated with placebo (DP); diabetic treated with insulin (DI) and diabetic treated with insulin plus resveratrol (DIR). After 30 days of treatment, 24-hour urine was collected; then, blood, soleus muscle, proximal small intestine, renal cortex and liver were sampled. Specific glucose transporter proteins were analyzed (Western blotting) in each territory of interest. Solute carrier family 2 member 2 (Slc2a2), phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase catalytic subunit (G6pc) mRNAs (qPCR), glycogen storage and sirtuin 1 (SIRT1) activity were analyzed in liver.
Diabetes induction increased blood glucose, plasma fructosamine concentrations, and glycosuria. Insulin therapy partially recovered the glycemic control; however, resveratrol as adjunctive therapy additionally improved glycemic control and restored plasma fructosamine concentration to values of non-diabetic rats. Resveratrol did not alter the expression of the glucose transporters GLUT2 and SGLT1 in the intestine, GLUT2 and SGLT2 in kidney and GLUT4 in soleus, suggesting that fluxes of glucose in these territories were unaltered. Differently, in liver, resveratrol promoted a reduction in Slc2a2, Pck1, and G6pc mRNAs, as well as in GLUT2 protein (P < 0.05, DIR vs. DI); besides, it increased (P < 0.01, DIR vs. DI) the hepatic glycogen content, and SIRT1 protein.
Resveratrol is able to improve glycemic control in insulin-treated T1D-like rats. This effect seems not to involve changes in glucose fluxes in the small intestine, renal proximal tubule, and soleus skeletal muscle; but to be related to several changes in the liver, where downregulation of Slc2a2/GLUT2, Pck1, and G6pc expression was observed, favoring reduction of glucose production and efflux. Besides, resveratrol increased SIRT1 nuclear protein content in liver, which may be related to the observed gene expression regulations.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27366200</pmid><doi>10.1186/s12986-016-0103-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-7075 |
| ispartof | Nutrition & metabolism, 2016-06, Vol.13 (1), p.44-44, Article 44 |
| issn | 1743-7075 1743-7075 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4928352 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Diet therapy Genetic aspects Metabolism Nutrition Physiological aspects Resveratrol Type 1 diabetes |
| title | Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A30%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resveratrol%20improves%20glycemic%20control%20in%20insulin-treated%20diabetic%20rats:%20participation%20of%20the%20hepatic%20territory&rft.jtitle=Nutrition%20&%20metabolism&rft.au=Yonamine,%20Caio%20Yogi&rft.date=2016-06-29&rft.volume=13&rft.issue=1&rft.spage=44&rft.epage=44&rft.pages=44-44&rft.artnum=44&rft.issn=1743-7075&rft.eissn=1743-7075&rft_id=info:doi/10.1186/s12986-016-0103-0&rft_dat=%3Cgale_pubme%3EA468882702%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1801255188&rft_id=info:pmid/27366200&rft_galeid=A468882702&rfr_iscdi=true |